OncoMatch/Bladder Cancer (Urothelial)/HER2 (ERBB2)

Bladder Cancer (Urothelial)HER2 (ERBB2) Clinical Trials

19 recruiting trials·Updated daily from ClinicalTrials.gov

HER2 overexpression or amplification occurs in approximately 10–15% of advanced urothelial carcinoma and has emerged as a targetable alteration following T-DXd activity in solid tumors broadly. Disitamab vedotin, a HER2-directed ADC, received FDA Breakthrough Designation in urothelial cancer. Trials investigate T-DXd, disitamab vedotin alone and in combination with pembrolizumab, and bispecific HER2 antibodies in HER2-altered urothelial carcinoma.

Match trials to my profile Clinician mode →

Top recruiting

Top recruiting HER2 (ERBB2) Bladder Cancer (Urothelial) trials

Ranked by phase and US site count.

See all trials matched to your profile →

Phase 3

A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma

RemeGen Co., Ltd.

Phase 2/Phase 3

DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations

Cancer Research UK

Phase 2157 US sites

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Seagen, a wholly owned subsidiary of Pfizer

Phase 2

Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladder Cancer

Shanxi Province Cancer Hospital

Phase 2

Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder Cancer

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2

Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)

Sun Yat-sen University

Additional trials

More HER2 (ERBB2) Bladder Cancer (Urothelial) trials

Phase 2

NCT06695845A Phase 2 Study of Zanidatamab in Patients With HER2-expressing TumorsPhase 216 US sites NCT05417594Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid MalignanciesPhase 1/Phase 211 US sites NCT06760819A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)Phase 211 US sites

Phase 1

NCT05614739FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3Phase 141 US sites NCT07660055Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid TumorsPhase 11 US site NCT06253871A Phase 1/1b Study of IAM1363 in HER2 CancersPhase 129 US sites NCT06293898Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid TumorsPhase 117 US sites NCT03740256Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid TumorsPhase 11 US site

5 international trials (no US sites)

NCT05917158A Study of RC48-ADC Combined with JS001 for Postoperative Adjuvant Treatment of Upper Tract Urothelial CarcinomaPhase 2 NCT05943379RC48-ADC in Combination With Gemcitabine in High Risk NMIBC SubjectsPhase 2 NCT07309770Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard TherapiesPhase 2 NCT06341400RC48 Combined with Toripalimab As Neoadjuvant Therapy for Cisplatin Ineligible MIBC PatientsPhase 1/Phase 2 NCT05944237HTL0039732 in Participants With Advanced Solid TumoursPhase 1/Phase 2

Other Bladder Cancer (Urothelial) biomarkers

Browse other molecular targets with active Bladder Cancer (Urothelial) trials.

PD-L1 (CD274)FGFR3

← All Bladder Cancer (Urothelial) clinical trials